Myovant Sciences Ltd.
MYOVNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MYOV. That does not mean none is planned.
Get an email about MYOV's next catalysts
Track Myovant Sciences (MYOV) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
0 upcoming, 1 past
No catalysts found.
Market Overview
Stock performance and key metrics
Estradiol/norethindrone acetate
Heavy Menstrual Bleeding
Relugolix
Endometriosis Related Pain
Leuprolide Acetate
Prostate Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Estradiol/norethindrone acetate | Phase 3 | Heavy Menstrual Bleeding | - | - |
Relugolix | Phase 3 | Endometriosis Related Pain | - | - |
Leuprolide Acetate | Phase 3 | Prostate Cancer | - | - |
Frequently asked questions
What is in Myovant Sciences Ltd.'s drug pipeline?β
CatalystAlert tracks 3 drug candidates in Myovant Sciences Ltd.'s (MYOV) pipeline across Phase 3. Its lead program is Estradiol/norethindrone acetate (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Myovant Sciences Ltd.'s next FDA catalyst?β
CatalystAlert tracks every upcoming catalyst for Myovant Sciences Ltd. (MYOV) β PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings β each confidence-rated as confirmed, estimated or AI-detected.
How do I track MYOV biotech catalysts?β
Add MYOV to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Myovant Sciences Ltd.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β sourced from ClinicalTrials.gov, FDA and SEC filings.
